Imfinzi-based perioperative regimen approved in the EU for resectable NSCLC based on AEGEAN Ph 3 trial results April 8, 2025
European Commission approves SC RYBREVANT (amivantamab) for the treatment of patients with advanced EGFR-mutated NSCLC April 8, 2025
RYBREVANT (amivantamab-vmjw) + LAZCLUZE (lazertinib) outperform osimertinib with a significant OS benefit in patients with EGFR-mutated NSCLC April 2, 2025
In LAURA Ph 3 trial, Tagrisso continues to demonstrate improved OS trend in unresectable, Stage III setting April 2, 2025
Both Prolonged Median OS and Long Tail of Survival in Ph 2a Trial of CAN-2409 in Advanced NSCLC Patients Non-Responsive to ICI Treatment Reported April 2, 2025
Positive CHMP Opinion for Neoadjuvant Opdivo + Chemo Followed by Surgery and Adjuvant Opdivo for Resectable NSCLC in Patients with Tumor Cell PD-L1 Expression ≥1% April 2, 2025
Ph 3 Trial Results for Ivonescimab in Head-to-Head Comparison with Pembrolizumab published in The Lancet March 11, 2025
Plans announced for Ph 2 trial of stenoparib + temozolomide for the treatment of recurrent SCLC March 11, 2025
Imfinzi-based perioperative regimen recommended for approval in the EU by CHMP for resectable NSCLC March 4, 2025
Neoadjuvant Opdivo® + Chemo Demonstrate Statistically Significant and Clinically Meaningful OS in Resectable NSCLC February 25, 2025
Zongertinib receives Priority Review from US FDA for the treatment of HER2-mutant advanced NSCLC February 25, 2025
IDEAYA and Gilead Sciences to Evaluate Combination of Trodelvy and IDE397 in MTAP-Deletion NSCLC February 19, 2025
Immuneering’s Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab) Announced February 11, 2025
Positive updated data from THIO-101 pivotal Ph 2 trial of THIO + Libtayo in patients with advanced NSCLC who failed two or more SOC regimens announced February 11, 2025
US FDA Grants Orphan Drug Designation to 225Ac-SSO110 (satoreotide) for the treatment of patients with SCLC February 11, 2025
Nuvation Bio Announces EAP in the US for Taletrectinib in Advanced ROS1-positive NSCLC February 5, 2025
Primary Endpoint Met in Ph 2b Trial of Zipalertinib in Patients with NSCLC with EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy February 5, 2025
